Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Source: GlobeNewswirePress Release – No. 10 / 2024
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 7, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third quarter / first nine months of 2024.
Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/4kd7ihsh. To receive telephone dial-in information and a unique personal access PIN, please register at https://register.vevent.com/register/BI9feb9ca116c04d17abb506491ebf0b90. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contacts:
| Adam Lange (Investors) |
| Investor Relations Officer |
| alange@zealandpharma.com |
| Neshat Ahmadi (Investors) |
| Investor Relations Manager |
| neahmadi@zealandpharma.com |
| Anna Krassowska, PhD (Investors and Media) |
| Vice President, Investor Relations & Corporate Communications |
| akrassowska@zealandpharma.com |
